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Abstract
Most neuroblastoma cell lines do not express apical
caspases 8 and 10, which play a key role in mediating
tumor necrosis factor–related apoptosis-inducing li-
gand (TRAIL) cytotoxicity in a variety of malignant cell
types. In this study, we demonstrated that TRAIL
induced a moderate but significant increase of apop-
tosis in the caspase 8/10–deficient SK-N-SH neuro-
blastoma cell line, through activation of a novel
caspase 9/7 pathway. Concomitant to the induction
of apoptosis, TRAIL also promoted a significant
increase of prostaglandin E2 (PGE2) release by SK-
N-SH cells. Moreover, coadministration of TRAIL plus
indomethacin, a pharmacological inhibitor of cyclo-
oxygenase (COX), showed an additive effect on SK-
N-SH cell death. In spite of the ability of TRAIL to
promote the phosphorylation of both ERK1/2 and
p38/MAPK, which have been involved in the control
of COX expression/activity, neither PD98059 nor
SB203580, pharmacological inhibitors of the ERK1/2
and p38/MAPK pathways, respectively, affected either
PGE2 production or apoptosis induced by TRAIL.
Finally, both induction of apoptosis and PGE2
release were completely abrogated by the broad
caspase inhibitor z-VAD-fmk, suggesting that both
biologic end points were regulated in SK-N-SH cells
through a caspase 9/7–dependent pathway.
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Introduction
Tumor necrosis factor (TNF)-a is the prototypical member
of the structurally related TNF family of cytokines, which
includes TNF-related apoptosis-inducing ligand (TRAIL)/
Apo-2L [1,2]. TRAIL exists as either a type II membrane
protein or as a soluble protein [3], and specifically binds to
four transmembrane TRAIL receptors belonging to the
TNF-R family. Although TRAIL-R1 and TRAIL-R2 trans-
duce apoptotic signals, TRAIL-R3 and TRAIL-R4 are ho-
mologous to TRAIL-R1 and TRAIL-R2 in their cysteine-rich
extracellular domain but lack intracellular death domain and
apoptosis-inducing capability [4]. Homotrimerization of TRAIL-
R1 or TRAIL-R2 by TRAIL induces the recruitment of the
adapter molecule FADD [4], which facilitates transproteolysis
and consequent activation of the cell death machinery, mainly
by inducing proximity between apical procaspases 8 and 10
molecules, which possess weak protease activity [5]. Although
TRAIL-R3 and/or TRAIL-R4 has been proposed to function as
a decoy receptor, protecting normal cells from apoptosis, its
protective role has been questioned in more recent studies [4].
It has been shown that TRAIL induces apoptosis in a variety
of malignant cells of neuronal origin, including a subset of
neuroblastomas [6–10], which are the most common extracra-
nial solid tumors of childhood. It should be noticed that, despite
recent advances in chemotherapeutic treatment options, the
overall prognosis for advanced neuroblastomas remains dis-
mal. It has been proposed that resistance to apoptosis is one of
the mechanisms that contribute to the aggressive behavior of
advanced-stage neuroblastomas, particularly in older children.
Importantly, these aggressive tumor behavior and unfavorable
outcome have been related to the fact that a large percentage
of neuroblastomas does not express apical caspases 8 and 10
[11]. On these bases, the aim of the present study was to
investigate the ability of TRAIL to modulate signal transduction
pathways involved in the control of cell death in neuroblas-
toma cells defective for apical caspases 8 and 10, using the
SK-N-SH cell line as a model system.
Materials and Methods
Materials
Recombinant histidine6 (His)– tagged TRAIL was pro-
duced in bacteria and purified by chromatography on Ni2+
affinity resin. Each batch of recombinant TRAIL was tested
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for cytotoxicity on the TRAIL-sensitive Jurkat cell line, as
previously described [12]. The absence of endotoxin con-
tamination in the recombinant TRAIL preparation (<0.1
endotoxin U/ml) was assessed by Limulus Amoebocyte
Lysate assay (BioWhittaker, Walkersville, MD). Polymyxin
B was purchased from Calbiochem (La Jolla, CA) and
recombinant IL-1b was purchased from Roche Molecular
Biochemicals (Mannheim, Germany).
The broad caspase inhibitor z-VAD-fmk (Calbiochem)
was used at the final concentration of 20 mM. Pharmacolog-
ical inhibitors of the ERK (PD98059) and p38/MAPK
(SB203580) pathways (both from Calbiochem) were used
at the final concentration of 50 and 10 mM, respectively.
Indomethacin [nonselective cyclooxygenase (COX) inhibitor;
Sigma, St. Louis, MO] was added at 20 mM.
Cells and Assessment of Apoptosis
Human neuroblastoma SK-N-SH and SK-N-MC cell lines
was obtained from the American Tissue Culture Collection
and cultured in plastic tissue culture dishes (Corning, New
York, NY). At different times posttreatment with TRAIL,
samples were analyzed by: 1) scoring the total number of
viable cultured cells by light microscopy examination; and 2)
evaluating the degree of apoptosis by DAPI and fluores-
cence microscopy, or 3) by propidium iodide (PI) and flow
cytometry analysis. For morphologic observations and anal-
yses of neuroblastoma cell cultures, images were recorded
on an Axioplan II microscope (Zeiss) equipped with a Cool-
Scan (Photometrics) video camera.
Phenotypic Analysis
Surface cellular antigens and apoptosis were analyzed by
flow cytometry. The expression of TRAIL-R1, TRAIL-R2,
TRAIL-R3, and TRAIL-R4 was analyzed by indirect staining
using antihuman TRAIL-R1, TRAIL-R2, TRAIL-R3, and
TRAIL-R4 monoclonal antibodies (all from Alexis, Lausanne,
Switzerland) followed by phycoerythrin (PE)–conjugated
rabbit antimouse IgG (Sigma). Aspecific fluorescence was
assessed by using normal mouse isotype-matched IgG,
followed by the second layer as above. Analyses were
performed by using a FACScan flow cytometer (Becton
Dickinson, San Jose`, CA) and the Lysis II software (Becton
Dickinson).
Western Blot Analysis
Cells were harvested in lysis buffer containing 1% Triton
X-100, Pefablock (1 mM), aprotinin (10 mg/ml), pepstatin (1
mg/ml), leupeptin (10 mg/ml), NaF (10 mM), and Na3VO4 (1
mM). Protein determination was performed by Bradford
assay (Bio-Rad, Richmond, CA). Equal amounts of protein
(50 mg) for each sample were migrated in acrylamide gels
and blotted onto nitrocellulose filters. The following anti-
bodies were used: rabbit antibodies anti-ERK1/2, anti–
phospho-ERK1/2, anti –p38/MAPK, anti –phospho-p38/
MAPK (all from New England Biolaboratories, Beverly,
MA), and anti –poly (ADP-ribose) polymerase (PARP)
(Santa Cruz Biotechnology, Santa Cruz, CA); mouse
monoclonal antibodies antiapical caspases 8, 9, and 10;
Figure 1. Surface expression of TRAIL receptors and profile of procaspases
in SK-N-SH cells. (A) Surface TRAIL receptor expression was evaluated by
flow cytometry. Shadowed histograms represent cells stained with antibodies
specific for the indicated TRAIL receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3,
and TRAIL-R4), whereas the unshadowed histogram represents the back-
ground fluorescence obtained from the staining of the same cultures with
isotype-matched control antibodies. (B) Procaspases expressed by SK-N-SH
and, for comparison with SK-N-MC, analyzed by Western blot. A representa-
tive of four separate experiments is shown.
458 TRAIL Activates a Caspase 9/7–Dependent Pathway Zauli et al.
Neoplasia . Vol. 5, No. 5, 2003
antieffector caspases 3, 6, and 7 (New England Biolabora-
tories); antitubulin (Sigma); and anti–COX-1 and anti–COX-
2 (Cayman Chemical, Ann Arbor, MI). After incubation with
peroxidase-conjugated antirabbit or antimouse IgG (Sigma),
specific reactions were revealed with the ECL Western
blotting detection reagent. Membranes were stripped by
incubation in Re-Blot 1  Ab stripping solution (Chemicon
International, Temecula, CA) and reprobed for the respective
total protein kinase content or tubulin for verifying loading
evenness. Densitometric values were estimated by the
ImageQuant software (Molecular Dynamics, Piscataway,
NJ). Multiple film exposures were used to verify the linearity
of the samples analyzed and to avoid saturation of the film.
Measurement of Prostanoids
Prostaglandin E2 (PGE2) release was measured in the
supernatants of cell cultures, using previously validated
radioimmunoassays [13]. In inhibition experiments, cells
were preincubated for 40 minutes with the indicated
inhibitors. Supernatants were collected and stored at
80jC until prostanoid measurement. Experiments were
always performed in duplicate.
Figure 2. Evaluation of cytotoxic effects of TRAIL on SK-N-SH. Cells
were exposed to TRAIL and examined for apoptosis and cell viability
by PI staining and flow cytometry (A), DAPI staining and fluorescence
microscopy (B), and light microscopy (C). (A) Data are expressed as
mean±SD of four experiments performed in duplicate. Statistically
significant ( P < .05) differences between TRAIL-treated and control
cultures were marked by an asterisk. (B, C) Shown are single fields
that are representative of untreated (panels a) and TRAIL-treated
(panels b) cultures. Original magnification,  40. (B) Inset shows a
magnification of a representative apoptotic SK-N-SH cell (arrow).
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Statistical Analysis
Data were analyzed using the two-tailed, two-sample t-
test (Minitab Statistical Analysis Software, State College,
PA). Values of P < .05 were considered significant.
Results
TRAIL Induces a Detectable Increase of Apoptosis in
SK-N-SH Cells
Flow cytometry analysis of the caspase 8/10–defective
SK-N-SH neuroblastoma cell line showed surface levels of
TRAIL-R2 and TRAIL-R4 and undetectable or very low
expression of TRAIL-R1 and TRAIL-R3 (Figure 1A). A similar
patter of expression of TRAIL receptors has been recently
shown to characterize the SK-N-MC neuroblastoma cell line
[14], as well as human cortical neurons [15]. The lack of
apical caspases 8 and 10, previously documented by Eggert
et al. [16], was confirmed by Western blot analysis in the SK-
N-SH cell clone used in this study (Figure 1B). However, the
SK-N-MC cell line expressed both procaspases 8 and 10
(Figure 1B).
In spite of the lack of caspases 8 and 10, recombinant
TRAIL induced a reproducible and significant (P < .05)
increase of apoptosis in SK-N-SH cells, evaluated by either
PI staining and flow cytometry (Figure 2A), or DAPI staining
and fluorescence microscopy (Figure 2B). Such increase of
apoptosis was accompanied by a concomitant decrease in
the number of viable attached cultured cells (Figure 2C).
The increase of apoptosis in the SK-N-SH cell line peaked
at 3 to 6 hours, never exceeding 20% over the control,
whereas we have previously shown that TRAIL-mediated
apoptosis in SK-N-MC peaked at 24 hours, reaching 50%
over the control [14].
Figure 3. Evaluation of TRAIL-induced caspase activation in SK-N-SH. The effect of TRAIL on caspase activation was evaluated at the indicated times by
immunoblotting analysis. Procaspase forms, intact PARP, and cleaved (arrowheads) products are indicated. Representative results of four separate experiments
are shown.
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We reasoned that although caspases 8 and 10 have been
shown to play a key role in transducing the apoptotic signal of
TRAIL in a variety of malignant cell types and, in particular, in
neuroblastomas [7,16–19], it was still possible that caspases
other than caspases 8 and 10 were involved in mediating
TRAIL-induced apoptosis in SK-N-SH cells. Among the
different caspases expressed by SK-N-SH cells, we found
that TRAIL induced a rapid cleavage of procaspases 9 and 7,
as well as of PARP, without affecting the levels of procas-
pases 3 and 6 (Figure 3). These findings suggest that TRAIL
activates a mitochondrial caspase–dependent pathway to
stimulate apical caspase 9 and effector caspase 7 in these
cells. In agreement with our findings, it has been recently
shown that TRAIL activates a caspase 8–independent apo-
ptotic pathway in normal prostate epithelial cells [20]. How-
ever, we have previously shown that TRAIL activates a
canonical caspase 8–dependent pathway in SK-N-MC [14].
TRAIL Upregulates the In Vitro Prostanoid Production and
Release by SK-N-SH Cells
Two distinct isoforms COX-1 and COX-2, also known as
PGH synthases, are known to catalyze one of the rate-limiting
steps in prostanoid biosynthesis [21]. Because COX activation
plays a relevant role in the control of neuronal cell survival
[22,23] by counteracting p53- or genotoxin stress–induced
apoptosis [24], the amount of prostanoid production (Figure
4A) and the expression of the different COX isoenzymes
(Figure 4B) were next explored in SK-N-SH cells treated with
TRAIL or IL-1b, used as positive control [25]. TRAIL induced a
significant (P < .01) increase in PGE2 release, peaking
between 3 and 6 hours posttreatment. Polymyxin B, an
inhibitor of lipopolysaccharide (LPS), did not abrogate TRAIL
effects on COX products, ruling out that potential contaminat-
ing LPS in TRAIL preparations might account for the TRAIL-
induced increase of PGE2 (Figure 4A). As expected, IL-1b
also significantly (P < .01) increased prostanoid production,
which peaked 24 hours posttreatment (Figure 4A). In Western
blot analysis, untreated SK-N-SH expressed both COX-1 and
COX-2 (Figure 4B). Although IL-1b markedly upregulated
COX-2 without affecting COX-1 protein levels, TRAIL did not
affect the expression levels of both COX isoforms (Figure 4B).
Indomethacin Potentiates TRAIL-Mediated Apoptosis of SK-
N-SH Cells
Because accumulating evidence indicates that COX ac-
tivity and prostaglandin synthesis play an important role in
Figure 4. Time course analyses of PGE2 release and COX expression
in SK-N-SH cells in response to TRAIL. SK-N-SH cells were exposed
to either TRAIL or IL-1 for analysis of spontaneous release of PGE2
(A) and evaluation of COX-1 and COX-2 expression (B). (A) Serum-
free culture supernatants were harvested at the indicated times after
treatment of cells with IL-1 or TRAIL in the presence or absence of
polymyxin B (Polym). Data are expressed as mean±SD of four
experiments performed in duplicate. Statistically significant ( P < .05)
differences between TRAIL-treated or IL-1treated and control
cultures were marked by an asterisk. (B) Cell lysates were analyzed
for COX-1 and COX-2 expression by Western blotting using specific
antibodies to each. Equal loading was confirmed by tubulin staining.
One of four experiments with similar results is shown.
TRAIL Activates a Caspase 9/7–Dependent Pathway Zauli et al. 461
Neoplasia . Vol. 5, No. 5, 2003
the promotion of various proliferative diseases including
cancers [22,24,26–29], to elucidate whether the TRAIL-
mediated PGE2 production might affect TRAIL cytotoxicity
in SK-N-SH cells, cells were cotreated with TRAIL plus the
nonselective COX inhibitor indomethacin [26]. As expected,
indomethacin suppressed basal, TRAIL-mediated, and IL-
1b–mediated PGE2 production (Figure 5). More importantly,
a significant (P < .05) increase of cytotoxicity was observed
in cells cotreated with TRAIL+indomethacin with respect to
cells treated with TRAIL alone. However, minimal or absent
cytotoxicity was noticed in cells cultured with indomethacin
or IL-1b, used alone or in combination (Figure 5). These data
suggest that either COX-derived prostanoids contribute to
protect against TRAIL-mediated cytotoxicity, or that indo-
methacin potentiated TRAIL cytotoxicity through a prosta-
noid-independent mechanism [30].
Both TRAIL-Mediated Apoptosis and Increase of Prosta-
noids are Abrogated by Caspase Inhibitors But Not by
Inhibitors of Mitogen-Activated Protein Kinase (MAPK)
Pathways
It has been previously shown that MAPKs participate in
the regulation of COX isoenzyme expression and activity
[25,31,32] and that TRAIL upregulates ERK1/2 in SK-N-
MC cells [14]. Therefore, we next investigated whether
TRAIL activates members of the MAPK family in SK-N-
SH cells by analyzing the phosphorylated forms of these
kinases by Western blot. As shown in Figure 6, IL-1b, used
as a positive control [25], induced a rapid phosphorylation
of both ERK1/2 (between 1 and 5 minutes) and p38/MAPK
(1–10 minutes). TRAIL also induced the phosphorylation
of both ERK1/2 (between 5 and 45 minutes) and p38/
MAPK (between 1 and 3 hours) but with a delayed kinetics
with respect to the IL-1b.
In the last group of experiments, pharmacological inhib-
itors for each MAPK pathway and the pan-caspase inhibitor
z-VAD-fmk were used to evaluate the effect of each path-
way on TRAIL-induced PGE2 production and apoptosis.
The only pharmacological compound showing a strong (P
< .01) inhibition of both TRAIL-mediated apoptosis (Figure
7A) and PGE2 production (Figure 7B) in SK-N-SH cells was
z-VAD-fmk. However, neither PD98059 nor SB203580,
pharmacological inhibitors of the ERK1/2 and p38/MAPK
pathways, respectively, showed significant effects on either
of these two biologic end points. Thus, although the ERK
pathway has been involved in anticancer drug– induced
apoptosis in neuroblastoma cells [33], neither of these two
pathways contributed significantly to TRAIL-mediated bio-
logic effects in this neuronal cell model. However,
SB203580 significantly (P < .01) decreased the ability of
IL-1b to induce prostanoid production without affecting the
degree of apoptosis (Figure 7, A and B), through the
inhibition of COX-2 protein expression (Figure 7C).
Discussion
Neuroblastoma cells are derived from sympathetic neuro-
nal cells, which, in early development, are dependent on
nerve growth factor (NGF) and neurotrophin-3 (NT3) for
growth [34]. It has been recently shown that among 18
neuroblastoma cell lines showing various expression levels
of caspases 2, 3, and 9, caspases 8 and 10 mRNA
expression was detected in only 5 of 18 neuroblastoma
cell lines, which showed the highest susceptibility to TRAIL
cytotoxicity. Caspases 8 and 10 are closely related genes
Figure 5. Effect of indomethacin on TRAIL-induced PGE2 release and apoptosis. SK-N-SH cells were preincubated with indomethacin (Indo; 20 M) before
exposure to TRAIL or IL-1. Serum-free culture supernatants were harvested at 6 hours after treatment of cells with TRAIL or IL-1 in the presence or absence of
Indo (left panel). The percentage of apoptotic SK-N-SH cells was evaluated by PI staining and flow cytometry in cultures left untreated or treated with TRAIL, used
alone or in combination with Indo (right panel). Data are expressed as mean±SD of four experiments performed in duplicate. Statistically significant ( P < .05)
differences between cultures treated or not with Indo were marked by an asterisk.
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Figure 6. Time course analyses of ERK1/2 and p38/MAPK expression and activation in SK-N-SH cells in response to TRAIL. Cells were made quiescent by the
reduction of serum to 0.1% in culture medium overnight before stimulation for the indicated times with TRAIL or IL-1 (10 U/ml), used as positive control. Equal
amounts of cell lysates were analyzed for ERK1/2 (A), and p38/MAPK (B) activation by Western blot analyses using antibodies specific for the native form of the
kinases and for residues that are phosphorylated in each kinase upon activation. Protein bands were quantified by densitometry, and levels of P-ERK1/2 (A) and
P-p38 (B) were calculated for each time point, after normalization to ERK1/2 or p38, respectively, in the same sample. Unstimulated basal expression was set as
unity. One of four experiments with similar results is shown.
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that have both been mapped to 2q33–34, suggesting that
the two genes have evolved by tandem duplication. Thus,
it is possible that both genes are involved in the same
gene rearrangement, mutational event, or epigenetic
change [11,16].
The data of our study performed on the caspase 8/10–
deficient SK-N-SH cell line indicate that TRAIL may still
induce a significant increase of apoptosis through a caspase
9/7–dependent pathway, whose activation results in induc-
tion of apoptosis and increased production of PGE2. Consis-
tent with our findings, it has been recently shown that the
adaptor intracellular protein FADD activates two apoptosis
pathways in prostate epithelial cells. The first pathway
involves recruitment of apical caspase 8 through the death
effector domain, whereas the second one works through the
FADD death domain and does not involve caspase 8 or
caspase 10, but requires caspase 9 [20]. In this context,
induction of apoptosis in caspase 8/10–deficient neuroblas-
toma cell lines, including SK-N-SH, has been recently
reported using the antibiotic geldanamycin. This induction
of apoptosis was associated with proteolytic cleavage of
caspase 9 and PARP, and was accompanied by an increase
in cytochrome c release, suggesting that geldanamycin, like
TRAIL, induces cell death through a mitochondrial-mediated
apoptotic pathway [35].
The ability of TRAIL to upregulate COX activity and PGE2
release in SK-N-SH cells is also noteworthy. In fact, several
groups of investigators have reported that COX and its major
final product, PGE2, protect cells against apoptosis. Rat
intestinal epithelial cells overexpressing COX-2 were resis-
tant to butyrate-induced apoptosis and had elevated Bcl-2
protein expression, which was reserved by a COX inhibitor,
Figure 7. Effect of MAPK pharmacological inhibitors and caspase
pharmacological inhibitors on TRAIL-induced apoptosis, PGE2 pro-
duction, and COX-2 expression. (A) SK-N-SH cells were preincubated
with the indicated inhibitors (z-VAD = z-VAD-fmk; PD = PD98059; SB
= SB203580) before exposure to TRAIL. Evaluation of caspase
activation was performed by immunoblotting analysis. Intact and
cleaved (arrowhead) PARPs are indicated. Representative results of
three separate experiments are shown. (B) SK-N-SH cells were
preincubated with the indicated inhibitors and either left untreated or
exposed to TRAIL or IL-1. Serum-free culture supernatants were
harvested at 6 hours for analysis of PGE2 release. Data are expressed
as mean±SD of three experiments, performed in duplicate. Statistically
significant ( P < .05) differences between cultures treated or not with z-
VAD or SB were marked by an asterisk. (C) Cell lysates were
harvested and analyzed for COX-1 and COX-2 expression by Western
blotting after 24 hours of treatment with IL-1, used alone or in
combination with SB203580. Equal loading was confirmed by tubulin
staining. One of three experiments with similar results is shown.
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sulindac sulfide [27]. PGE2 inhibited apoptosis caused by a
COX inhibitor and induced Bcl-2 expression in human colon
cancer cells (HCA-7) [28]. Human lung adenocarcinoma
CL1.0 cells with high levels of COX-2 showed a remarkable
resistance to apoptosis induced by vinblastine by inducing an
Mcl-1–dependent survival mechanism [29]. More impor-
tantly, enhanced COX expression/activity may play a signif-
icant role in the resistance to chemotherapy-induced
apoptosis [29,36,37]. These studies are consistent with our
data that COX inhibition increases TRAIL-mediated apopto-
sis. Furthermore, the ability of TRAIL to simultaneously
activate a proapoptotic and an antiapoptotic pathway is not
completely unprecedented. In fact, Han et al. [24] have
recently demonstrated that p53 induces COX activation,
which counteracts p53- or genotoxic stress– induced apop-
tosis. This antiapoptotic effect has been proposed to be a
mechanism that abates cellular stresses associated with p53
induction. Although PGE2 has been proposed to protect
some cell types from apoptosis, a possible alternative mech-
anism for enhanced apoptosis by COX inhibitors was dis-
cussed nicely in a study demonstrating that apoptosis due to
nonsteroidal anti-inflammatory drugs is not likely to be relat-
ed to a reduction in prostaglandins but rather to an elevation
of the prostaglandin precursor arachidonic acid, which stim-
ulates ceramide production, a strong mediator of apoptosis
[30]. Although the MAPK pathways have been involved in
neurotoxicity [33,38], neither of these pathways appeared to
significantly contribute to both prostanoid production and
apoptosis induced by TRAIL in SK-N-SH cells.
Conclusion
We have documented here for the first time the existence of
a caspase-dependent pathway, which does not require the
presence of apical caspases 8 and 10 and has two distinct
biologic end points: transient increase of apoptosis and
upregulation of PGE2 release in neuroblastoma cells. More-
over, the cooperative effects of indomethacin with TRAIL in
inducing the cell death of caspase 8/10–deficient neuroblas-
tomas demonstrated in our present study provides a mech-
anistic basis for the potential use of COX inibitors, in
combination with TRAIL, in the treatment of neuroblastomas.
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